Return to site

Filter Integrity Test Market is projected to reach USD 79 million by 2024

· Medical Devices,Biotechnology

The filter integrity test market is projected to reach USD 79 million by 2024 from USD 59 million in 2018, at a CAGR of 5.0% during the forecast period.

Factors such as increasing R&D spending, growth in the biopharmaceutical industry, and increasing purity requirements in the end-user market are driving the growth of the market.

The increasing demand for biopharmaceuticals and implementation of drug safety guidelines by the FDA are the major factors driving the growth of the filter integrity test market in North America.

The market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Significant investments by key market players, increasing government support, developing R&D infrastructure, and growing expertise and academic excellence are the major factors fueling the growth of the market in the Asia Pacific.

Key Players
The major players in the filter integrity test market are Merck KGaA (Germany), Danaher Corporation/Pall Corporation (US), Sartorius (Germany), Donaldson Company (US), Parker Hannifin Corporation (US), Meissner Filtration Product (US), MDI Filtration Technologies (US), Thermo Fisher Scientific (US), Eaton Corporation (Ireland), and SH-Surway (China).

Sartorius is a prominent player in the market. The company has a wide range of product offerings, which include filter integrity tests, transfer equipment, bottles, and bags. The company mainly focuses on product innovation and has a strong geographic presence in Europe, the Americas, and the Asia Pacific. The company is expected to grow at a positive rate in the market due to its superior product offerings.

Merck is another major player in the filter integrity test market. The company has a strong geographic presence across the Americas, Europe, Asia Pacific, and the Middle East and Africa. Merck focuses on inorganic strategies to maintain its leading position in this market. For instance, in 2018, the company signed a MoU with Schneider Electric (France) to automate biopharmaceutical processes for China’s biopharmaceutical industry.

To know about the assumptions considered for the study, download the pdf brochure

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly